Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial

BACKGROUND: The enterovirus 71 (EV71) vaccine produced by Wuhan Institute of Biological Products Co., Ltd. (WIBP) (B-EV71) has been given to children aged 6-35 months, and it has shown good safety, immunogenicity and efficacy. However, the administration of EV71 vaccine in children aged 36-71 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Yeqing, Zhang, Xinyue, Chen, Jinhua, Chen, Wei, Wang, Zhao, Li, Qiong, Duan, Kai, Wei, Sheng, Yang, Beifang, Qian, Xiaoai, Li, Jiahong, Hang, Lianju, Deng, Shaoyong, Li, Xinguo, Guo, Changfu, Shen, Heng, Liu, Yan, Deng, Peng, Xie, Tingbo, Li, Qingliang, Li, Li, Du, Hongqiao, Mao, Qunying, Gao, Fan, Lu, Weiwei, Guan, Xuhua, Huang, Jiao, Li, Xiuling, Chen, Xiaoqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340505/
https://www.ncbi.nlm.nih.gov/pubmed/35923425
http://dx.doi.org/10.1016/j.eclinm.2022.101596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340505/
https://www.ncbi.nlm.nih.gov/pubmed/35923425
http://dx.doi.org/10.1016/j.eclinm.2022.101596

Ejemplares similares